CJC-1295 / GHRP-6 blend
Multi peptide
ABOUT
A research-market blend generally pairing Modified GRF 1-29, sold as “CJC-1295 without DAC,” with GHRP-6. FDA documents products under this component formula, but there is no standard ratio or approved combination.
WHAT IS IN IT · 2 COMPOUNDS
Check the amounts on the vial rather than assuming them from the blend name.
EVIDENCE OVERVIEW
Too little published work to judge either way
WHAT THIS MEANS
Insufficient evidence. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
The GHRH-receptor action of Modified GRF 1-29 is paired with ghrelin/GH-secretagogue-receptor activation by GHRP-6. GHRP-6 is notably orexigenic, so appetite stimulation is a mechanistic and observed component effect rather than evidence of a benefit from the blend.
PHARMACOKINETICS
GHRP-6 has been characterised in a nine-person human pharmacokinetic study, but the pair and its changing market ratios have not. A co-vial prevents either component being adjusted without changing the other.
REVIEW
PUBLISHED PAIR RECORDS
with CJC-1295 (without DAC)
Same substance taken twice: blend already contains this compoundCJC-1295 / GHRP-6 blend already contains CJC-1295 (without DAC). Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with GHRP-6
Same substance taken twice: blend already contains this compoundCJC-1295 / GHRP-6 blend already contains GHRP-6. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / Ipamorelin blend
Overlapping blends: the same compounds appear in bothCJC-1295 / Ipamorelin blend and CJC-1295 / GHRP-6 blend both contain CJC-1295 (without DAC). Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / GHRP-2 blend
Overlapping blends: the same compounds appear in bothCJC-1295 / GHRP-2 blend and CJC-1295 / GHRP-6 blend both contain CJC-1295 (without DAC). Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / Hexarelin blend
Overlapping blends: the same compounds appear in bothCJC-1295 / GHRP-6 blend and CJC-1295 / Hexarelin blend both contain CJC-1295 (without DAC). Taking both means those shared components arrive from two vials at once, at a combined amount neither product states, while the components unique to each still arrive at their own. Because both are sold at fixed manufacturer ratios, neither can be adjusted to compensate for the other. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Ipamorelin
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains CJC-1295 (without DAC) and GHRP-6, and the catalogue holds a curated pair record between those components and Ipamorelin: CJC-1295 (without DAC) (growth-hormone axis: documented synergistic release); GHRP-6 (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with GHRP-2
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains CJC-1295 (without DAC) and GHRP-6, and the catalogue holds a curated pair record between those components and GHRP-2: CJC-1295 (without DAC) (growth-hormone axis: documented synergistic release); GHRP-6 (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Hexarelin
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains CJC-1295 (without DAC) and GHRP-6, and the catalogue holds a curated pair record between those components and Hexarelin: CJC-1295 (without DAC) (growth-hormone axis: documented synergistic release); GHRP-6 (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with MK-677
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains CJC-1295 (without DAC) and GHRP-6, and the catalogue holds a curated pair record between those components and MK-677: CJC-1295 (without DAC) (growth-hormone axis: documented synergistic release); GHRP-6 (same receptor class: overlapping ghrelin-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 with DAC
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains GHRP-6 and CJC-1295 (without DAC), and the catalogue holds a curated pair record between those components and CJC-1295 with DAC: GHRP-6 (growth-hormone axis: documented synergistic release); CJC-1295 (without DAC) (same receptor class: overlapping ghrh-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Sermorelin
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains GHRP-6 and CJC-1295 (without DAC), and the catalogue holds a curated pair record between those components and Sermorelin: GHRP-6 (growth-hormone axis: documented synergistic release); CJC-1295 (without DAC) (same receptor class: overlapping ghrh-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Tesamorelin
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains GHRP-6 and CJC-1295 (without DAC), and the catalogue holds a curated pair record between those components and Tesamorelin: GHRP-6 (growth-hormone axis: documented synergistic release); CJC-1295 (without DAC) (same receptor class: overlapping ghrh-receptor activity). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with IGF-1 LR3
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains CJC-1295 (without DAC) and GHRP-6, and the catalogue holds a curated pair record between those components and IGF-1 LR3: CJC-1295 (without DAC) (additive igf-1 receptor signalling); GHRP-6 (additive igf-1 receptor signalling). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with IGF-1 DES
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains CJC-1295 (without DAC) and GHRP-6, and the catalogue holds a curated pair record between those components and IGF-1 DES: CJC-1295 (without DAC) (additive igf-1 receptor signalling); GHRP-6 (additive igf-1 receptor signalling). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with follistatin-344
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains CJC-1295 (without DAC) and GHRP-6, and the catalogue holds a curated pair record between those components and Follistatin-344: CJC-1295 (without DAC) (converging on muscle growth from two different directions); GHRP-6 (converging on muscle growth from two different directions). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with AOD-9604
Inherited from a component of this blendCJC-1295 / GHRP-6 blend contains CJC-1295 (without DAC) and GHRP-6, and the catalogue holds a curated pair record between those components and AOD-9604: CJC-1295 (without DAC) (growth-hormone fragment that does not act through the growth-hormone receptor); GHRP-6 (growth-hormone fragment that does not act through the growth-hormone receptor). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
No study has examined this blend as a blend. A PubMed search for the product name returns no matching literature, so everything known about it is inference from its separate components, and the effect of giving them together at a fixed ratio is uncharacterised rather than known to be additive. Human work exists for GHRP-6 alone and for receptor-level GHRH/GHRP synergy, but no controlled trial evaluates this exact pair.
REPORTED EFFECTS
No combination safety dataset exists. GHRP-6 can markedly increase hunger and may affect glucose, prolactin, ACTH and cortisol; both components stimulate the GH/IGF-1 axis. FDA documentation of the marketed powder is evidence that it is sold, not that it is safe or effective.
RESEARCH LIMITATIONS
This is a summary of a blend, not a recommendation. Its composition is given as commonly marketed and is deliberately uncited: the only places it is stated are the shops selling it, which this catalogue does not link and does not treat as evidence. Treat the amounts as unverified, and note that blends sold under one name are not standardised between suppliers. Read the mechanism, pharmacokinetic, human-evidence and reported-effect fields separately: a mechanism is not an outcome, and a combination of mechanisms is not a combination of outcomes.
CURATED SOURCES · 4